Popular Articles

Siemens softens despite bagging contract
Siemens closed at Rs 571, down by 2.5% or Rs 14 on the BSE. The stock opened at Rs 590 and touched a high of Rs 605 and a low of Rs 565 during the day. A total of 272,659 shares were traded on the BSE as against the 2-week average of 109,271 shares.

Indian IT firms lift lid on hiring
Industry experts still remain cautious on numbers.

News of the day

US markets end off day's high
US Federal Reserve"s decision to keep rates near zero dragged the markets off the day"s high. The Dow added 30 points to 9,802. The Nasdaq was unchanged at 2,056.
Online Business

J&J Medical to launch insulin pumps in India by year-end

Johnson and Johnson Medical India, plans to introduce its insulin pump for diabetes patients in the country by end-this year, a top company official said. - Diabetes is poorly controlled in India: Study - Biocon inks pact with Amylin to develop diabetes therapy - Foresight plans 25 outlets in 3 yrs - Aurobindo Pharma receives Swissmedic approval - Johnson & Johnson expands portfolio; launches Neutrogena brand - Insulin prices may come down by 70% "We are planning to launch insulin pumps in India by this December," Johnson and Johnson Medical India, Managing Director, A Vaidheesh, said here. Johnson and Johnson Medical is a division of healthcare major, Johnson and Johnson, and is a leading global manufacturer of medical devices. The company will initially launch 3,000 insulin pumps and then 4,000 units next year, Vaidheesh added. Priced at between Rs 50,000-75,000 per pump, the device is designed and manufactured by its parent company, Johnson and Johnson, and would help regulate the insulin level in diabetic patients. The device will be imported from the US, where it is being manufactured and has proved efficient for users, Vaidheesh said. The device, attached to the patient"s body for 24-hours, helps monitor and regulate insulin levels while delivering the drug at a steady rate suited to an individual"s needs. The pump also needs a catridge which is priced at Rs 50 and needs to be refilled every day. The company is agressively concentrating on diabetics control in India as there was an immense potential in this segment, Vaidheesh said. The number of diabetics was growing in the country, he added, saying initially the company expects around 5 per cent of the total diabetic population in the country to use the company"s product.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):